Emerging resistance vs. losing response to immune check point inhibitors in renal cell carcinoma: two differing phenomena

Abstract

The introduction of immune checkpoint inhibitor (ICI) has revolutionized the treatment of metastatic renal cell carcinoma (mRCC) and has dramatically improved the outcomes of patients. The use of monotherapy or combinations of ICIs targeting PD-1/PD-L1 and CTLA-4, as well as the addition of ICIs with tyrosine kinase inhibitors, has significantly enhanced the overall survival of mRCC patients. Despite these promising results, there remains a subset of patients who either do not respond to treatment (primary resistance) or develop resistance to therapy over time (acquired resistance). Understanding the mechanisms underlying the development of resistance to ICI treatment is crucial in the management of mRCC, as they can be used to identify new targets for innovative therapeutic strategies. Currently, there is an unmet need to develop new predictive and prognostic biomarkers that can aid in the development of personalized treatment options for mRCC patients. In this review, we summarize several mechanisms of ICI resistance in RCC, including alterations in tumor microenvironment, upregulation of alternative immune checkpoint pathways, and genetic and epigenetic changes. Additionally, we highlight potential strategies that can be used to overcome resistance, such as combination therapy, targeted therapy, and immune modulation.

Keywords

Renal cell carcinoma / immunotherapy / immune checkpoint inhibitors / primary resistance / acquired resistance / immune exhaustion markers / immunosuppressive tumor microenvironment

References

[1] Rini BI,Escudier B.Renal cell carcinoma.Lancet2009;373:1119-32

[2] Siegel RL,Wagle NS.Cancer statistics, 2023.CA Cancer J Clin2023;73:17-48

[3] Delahunt B,Egevad L.International society of urological pathology grading and other prognostic factors for renal neoplasia.Eur Urol2014;66:795-8

[4] Choueiri TK.Systemic therapy for metastatic renal-cell carcinoma.N Engl J Med2017;376:354-66

[5] Motzer RJ,Tomczak P.Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma.J Clin Oncol2009;27:3584-90

[6] Motzer RJ,Oudard S.Phase 3 trial of everolimus for metastatic renal cell carcinoma: final results and analysis of prognostic factors.Cancer2010;116:4256-65

[7] Itsumi M.Immunotherapy for renal cell carcinoma.Clin Dev Immunol2010;2010:284581 PMCID:PMC3022170

[8] Roy AM,Tippit D,Verma R.Neoadjuvant cabozantinib in renal-cell carcinoma: a brief review.Clin Genitourin Cancer2020;18:e688-91

[9] Motzer RJ,McDermott DF.Nivolumab versus everolimus in advanced renal-cell carcinoma.N Engl J Med2015;373:1803-13

[10] Motzer RJ,McDermott DF.Nivolumab plus ipilimumab versus sunitinib in advanced renal-cell carcinoma.N Engl J Med2018;378:1277-90 PMCID:PMC5972549

[11] Albiges L,Burotto M.Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended 4-year follow-up of the phase III CheckMate 214 trial.ESMO Open2020;5:e001079 PMCID:PMC7703447

[12] Rini BI,Stus V.Pembrolizumab plus Axitinib versus Sunitinib for advanced renal-cell carcinoma.N Engl J Med2019;380:1116-27

[13] Motzer RJ,Haanen J.Avelumab plus axitinib versus sunitinib for advanced renal-cell carcinoma.N Engl J Med2019;380:1103-15 PMCID:PMC6716603

[14] Motzer RJ,Burotto M.Nivolumab plus cabozantinib versus sunitinib in first-line treatment for advanced renal cell carcinoma (CheckMate 9ER): long-term follow-up results from an open-label, randomised, phase 3 trial.Lancet Oncol2022;23:888-98 PMCID:PMC10305087

[15] Motzer R,Rha SY.Lenvatinib plus pembrolizumab or everolimus for advanced renal cell carcinoma.N Engl J Med2021;384:1289-300

[16] Chen DS.Oncology meets immunology: the cancer-immunity cycle.Immunity2013;39:1-10

[17] Keir ME,Guleria I.Tissue expression of PD-L1 mediates peripheral T cell tolerance.J Exp Med2006;203:883-95 PMCID:PMC2118286

[18] Keir ME,Freeman GJ.PD-1 and its ligands in tolerance and immunity.Annu Rev Immunol2008;26:677-704

[19] Krummel MF.CD28 and CTLA-4 have opposing effects on the response of T cells to stimulation.J Exp Med1995;182:459-65 PMCID:PMC2192127

[20] Ross K.Immune checkpoint inhibitors in renal cell carcinoma.Clin Sci2017;131:2627-42 PMCID:PMC5869245

[21] Fares CM,Drake CG,Hu-Lieskovan S.Mechanisms of resistance to immune checkpoint blockade: why does checkpoint inhibitor immunotherapy not work for all patients?.Am Soc Clin Oncol Educ Book2019;39:147-64

[22] Rizvi H,La K.Molecular determinants of response to anti-programmed cell death (PD)-1 and anti-programmed death-ligand 1 (PD-L1) blockade in patients with non-small-cell lung cancer profiled with targeted next-generation sequencing.J Clin Oncol2018;36:633-41 PMCID:PMC6075848

[23] Ladoire S,Apetoh L.Pathologic complete response to neoadjuvant chemotherapy of breast carcinoma is associated with the disappearance of tumor-infiltrating foxp3⁺ regulatory T cells.Clin Cancer Res2008;14:2413-20

[24] Chaudhary B.Regulatory T cells in the tumor microenvironment and cancer progression: role and therapeutic targeting.Vaccines2016;4:28 PMCID:PMC5041022

[25] Rudensky AY.Regulatory T cells and Foxp3.Immunol Rev2011;241:260-8 PMCID:PMC3077798

[26] Schmidt A,Krammer PH.Molecular mechanisms of treg-mediated T cell suppression.Front Immunol2012;3:51 PMCID:PMC3341960

[27] Curiel TJ,Zou L.Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival.Nat Med2004;10:942-9

[28] Tang Y,Guo S.An increased abundance of tumor-infiltrating regulatory T cells is correlated with the progression and prognosis of pancreatic ductal adenocarcinoma.PLoS One2014;9:e91551 PMCID:PMC3956642

[29] Shang B,Jiang SJ.Prognostic value of tumor-infiltrating FoxP3⁺ regulatory T cells in cancers: a systematic review and meta-analysis.Sci Rep2015;5:15179 PMCID:PMC4604472

[30] Griffiths RW,Gilham DE.Frequency of regulatory T cells in renal cell carcinoma patients and investigation of correlation with survival.Cancer Immunol Immunother2007;56:1743-53

[31] Rodríguez PC.Arginine regulation by myeloid derived suppressor cells and tolerance in cancer: mechanisms and therapeutic perspectives.Immunol Rev2008;222:180-91 PMCID:PMC3546504

[32] Kusmartsev S,Yoder D.Antigen-specific inhibition of CD8+ T cell response by immature myeloid cells in cancer is mediated by reactive oxygen species.J Immunol2004;172:989-99

[33] Ochoa AC,Hernandez C.Arginase, prostaglandins, and myeloid-derived suppressor cells in renal cell carcinoma.Clin Cancer Res2007;13:721s-6s

[34] Mantovani A,Locati M,Sica A.Macrophage polarization: tumor-associated macrophages as a paradigm for polarized M2 mononuclear phagocytes.Trends Immunol2002;23:549-55

[35] Hao NB,Fan YH,Zhang ZR.Macrophages in tumor microenvironments and the progression of tumors.Clin Dev Immunol2012;2012:948098 PMCID:PMC3385963

[36] Chanmee T,Konno K.Tumor-associated macrophages as major players in the tumor microenvironment.Cancers2014;6:1670-90 PMCID:PMC4190561

[37] Pollard JW.Tumour-educated macrophages promote tumour progression and metastasis.Nat Rev Cancer2004;4:71-8

[38] Van Ginderachter JA,Hassanzadeh Ghassabeh G.Classical and alternative activation of mononuclear phagocytes: picking the best of both worlds for tumor promotion.Immunobiology2006;211:487-501

[39] Noy R.Tumor-associated macrophages: from mechanisms to therapy.Immunity2014;41:49-61 PMCID:PMC4137410

[40] Tsutsui S,Suzuki K,Higashi H.Macrophage infiltration and its prognostic implications in breast cancer: the relationship with VEGF expression and microvessel density.Oncol Rep2005;14:425-31

[41] Zijlmans HJ,Baelde HJ,Kenter GG.The absence of CCL2 expression in cervical carcinoma is associated with increased survival and loss of heterozygosity at 17q11.2.J Pathol2006;208:507-17

[42] Gil M,Seshadri M.CXCL12/CXCR4 blockade by oncolytic virotherapy inhibits ovarian cancer growth by decreasing immunosuppression and targeting cancer-initiating cells.J Immunol2014;193:5327-37 PMCID:PMC4225176

[43] Rabin RL,Liao F,Stephany D.Chemokine receptor responses on T cells are achieved through regulation of both receptor expression and signaling.J Immunol1999;162:3840-50

[44] Najafi M,Mortezaee K.Contribution of regulatory T cells to cancer: a review.J Cell Physiol2019;234:7983-93

[45] Motz GT,Wang LP.Tumor endothelium FasL establishes a selective immune barrier promoting tolerance in tumors.Nat Med2014;20:607-15 PMCID:PMC4060245

[46] Braun DA,Burke KP.Progressive immune dysfunction with advancing disease stage in renal cell carcinoma.Cancer Cell2021;39:632-48.e8 PMCID:PMC8138872

[47] Zhang L,Zheng L.Lineage tracking reveals dynamic relationships of T cells in colorectal cancer.Nature2018;564:268-72

[48] Becht E,Lacroix L.Estimating the population abundance of tissue-infiltrating immune and stromal cell populations using gene expression.Genome Biol2016;17:218 PMCID:PMC5073889

[49] Giraldo NA,Pagès F.Orchestration and prognostic significance of immune checkpoints in the microenvironment of primary and metastatic renal cell cancer.Clin Cancer Res2015;21:3031-40

[50] Motzer RJ,Powles T.Avelumab plus axitinib versus sunitinib in advanced renal cell carcinoma: biomarker analysis of the phase 3 JAVELIN renal 101 trial.Nat Med2020;26:1733-41 PMCID:PMC8493486

[51] Voss MH,Hellmann MD.Correlation of degree of tumor immune infiltration and insertion-and-deletion (indel) burden with outcome on programmed death 1 (PD1) therapy in advanced renal cell cancer (RCC).J Clin Oncol2018;36:4518

[52] Rooney MS,Wu CJ,Hacohen N.Molecular and genetic properties of tumors associated with local immune cytolytic activity.Cell2015;160:48-61 PMCID:PMC4856474

[53] Zaretsky JM,Shin DS.Mutations associated with acquired resistance to PD-1 blockade in melanoma.N Engl J Med2016;375:819-29 PMCID:PMC5007206

[54] Boehm U,Groot M.Cellular responses to interferon-gamma.Annu Rev Immunol1997;15:749-95

[55] Garcia-Diaz A,Moreno BH.Interferon receptor signaling pathways regulating PD-L1 and PD-L2 expression.Cell Rep2017;19:1189-201 PMCID:PMC6420824

[56] Goodman AM,Kato S.Prevalence of PDL1 amplification and preliminary response to immune checkpoint blockade in solid tumors.JAMA Oncol2018;4:1237-44 PMCID:PMC6139049

[57] Shin DS,Escuin-Ordinas H.Primary resistance to PD-1 blockade mediated by JAK1/2 mutations.Cancer Discov2017;7:188-201 PMCID:PMC5296316

[58] Dhillon AS,Rath O.MAP kinase signalling pathways in cancer.Oncogene2007;26:3279-90

[59] Loi S,Beavis PA.RAS/MAPK activation is associated with reduced tumor-infiltrating lymphocytes in triple-negative breast cancer: therapeutic cooperation between MEK and PD-1/PD-L1 immune checkpoint inhibitors.Clin Cancer Res2016;22:1499-509 PMCID:PMC4794351

[60] Zhan T,Boutros M.Wnt signaling in cancer.Oncogene2017;36:1461-73 PMCID:PMC5357762

[61] Spranger S,Gajewski TF.Melanoma-intrinsic β-catenin signalling prevents anti-tumour immunity.Nature2015;523:231-5

[62] Peng W,Liu C.Loss of PTEN promotes resistance to T cell-mediated immunotherapy.Cancer Discov2016;6:202-16 PMCID:PMC4744499

[63] Cai C,Wu ZJ.Tim-3 expression represents dysfunctional tumor infiltrating T cells in renal cell carcinoma.World J Urol2016;34:561-7

[64] Thommen DS,Müller P.Progression of lung cancer is associated with increased dysfunction of T cells defined by coexpression of multiple inhibitory receptors.Cancer Immunol Res2015;3:1344-55

[65] Koyama S,Li YY.Adaptive resistance to therapeutic PD-1 blockade is associated with upregulation of alternative immune checkpoints.Nat Commun2016;7:10501 PMCID:PMC4757784

[66] Shayan G,Li J,Kane LP.Adaptive resistance to anti-PD1 therapy by Tim-3 upregulation is mediated by the PI3K-Akt pathway in head and neck cancer.Oncoimmunology2017;6:e1261779 PMCID:PMC5283618

[67] Ngiow SF,Jacquelot N.A threshold level of intratumor CD8+ T-cell PD1 expression dictates therapeutic response to Anti-PD1.Cancer Res2015;75:3800-11

[68] Oyewole-Said D,Vazquez-Perez J,Levitt JM.Beyond T-cells: functional characterization of CTLA-4 expression in immune and non-immune cell types.Front Immunol2020;11:608024 PMCID:PMC7770141

[69] Ribas A,Zaretsky J.PD-1 blockade expands intratumoral memory T cells.Cancer Immunol Res2016;4:194-203 PMCID:PMC4775381

[70] Jenkins RW,Flaherty KT.Mechanisms of resistance to immune checkpoint inhibitors.Br J Cancer2018;118:9-16 PMCID:PMC5765236

[71] Sormendi S.Hypoxia pathway proteins as central mediators of metabolism in the tumor cells and their microenvironment.Front Immunol2018;9:40 PMCID:PMC5796897

[72] Khan KA.Improving immunotherapy outcomes with anti-angiogenic treatments and vice versa.Nat Rev Clin Oncol2018;15:310-24

[73] Gopalakrishnan V,Nezi L.Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients.Science2018;359:97-103 PMCID:PMC5827966

[74] Lalani AA,Braun DA.Effect of antibiotic use on outcomes with systemic therapies in metastatic renal cell carcinoma.Eur Urol Oncol2020;3:372-81 PMCID:PMC9163676

[75] Derosa L,Spaziano M.Negative association of antibiotics on clinical activity of immune checkpoint inhibitors in patients with advanced renal cell and non-small-cell lung cancer.Ann Oncol2018;29:1437-44 PMCID:PMC6354674

[76] Tinsley N,Tan G.Cumulative antibiotic use significantly decreases efficacy of checkpoint inhibitors in patients with advanced cancer.Oncologist2020;25:55-63 PMCID:PMC6964118

[77] Bucsek MJ,MacDonald CR.β-adrenergic signaling in mice housed at standard temperatures suppresses an effector phenotype in CD8⁺ T cells and undermines checkpoint inhibitor therapy.Cancer Res2017;77:5639-51 PMCID:PMC5645237

[78] Mori K,Yanagisawa T.The effect of immune checkpoint inhibitor combination therapies in metastatic renal cell carcinoma patients with and without previous cytoreductive nephrectomy: a systematic review and meta-analysis.Int Immunopharmacol2022;108:108720

[79] Rassy E,Colomba E.Efficacy and safety of concomitant proton pump inhibitor and nivolumab in renal cell carcinoma: results of the GETUG-AFU 26 NIVOREN multicenter phase II study.Clin Genitourin Cancer2022;20:488-94

[80] Wolchok JD.The mechanism of anti-CTLA-4 activity and the negative regulation of T-cell activation.Oncologist2008;13 Suppl 4:2-9

[81] Zaremba A,Robert C.The concepts of rechallenge and retreatment with immune checkpoint blockade in melanoma patients.Eur J Cancer2021;155:268-80

[82] Atkins MB,Haas NB.Phase II study of nivolumab and salvage nivolumab/ipilimumab in treatment-naive patients with advanced clear cell renal cell carcinoma (HCRN GU16-260-Cohort A).J Clin Oncol2022;40:2913-23 PMCID:PMC9426835

[83] Grimm MO,Barthélémy P.Efficacy of nivolumab/ipilimumab in patients with initial or late progression with nivolumab: updated analysis of a tailored approach in advanced renal cell carcinoma (TITAN-RCC).J Clin Oncol2021;39:4576

[84] Pal SK,Tomczak P.Atezolizumab plus cabozantinib versus cabozantinib monotherapy for patients with renal cell carcinoma after progression with previous immune checkpoint inhibitor treatment (CONTACT-03): a multicentre, randomised, open-label, phase 3 trial.Lancet2023;402:185-95

[85] Choueiri TK,Hammers HJ.TiNivo-2: a phase 3, randomized, controlled, multicenter, open-label study to compare tivozanib in combination with nivolumab to tivozanib monotherapy in subjects with renal cell carcinoma who have progressed following one or two lines of therapy where one line has an immune checkpoint inhibitor.J Clin Oncol2022;40:TPS405

[86] Roy AM.Management of immune-mediated toxicities and their implications in the outcomes of advanced kidney cancer.Immunotherapy2023;15:397-400

[87] Burotto M,Escudier B.Nivolumab plus cabozantinib vs sunitinib for first-line treatment of advanced renal cell carcinoma (aRCC): 3-year follow-up from the phase 3 CheckMate 9ER trial.J Clin Oncol2023;41:603

[88] Fukumura D,Amoozgar Z,Jain RK.Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges.Nat Rev Clin Oncol2018;15:325-40 PMCID:PMC5921900

[89] Alfaro C,Gonzalez A.Influence of bevacizumab, sunitinib and sorafenib as single agents or in combination on the inhibitory effects of VEGF on human dendritic cell differentiation from monocytes.Br J Cancer2009;100:1111-9 PMCID:PMC2670006

[90] Huang Y,Dikov MM.Distinct roles of VEGFR-1 and VEGFR-2 in the aberrant hematopoiesis associated with elevated levels of VEGF.Blood2007;110:624-31 PMCID:PMC1924481

[91] Adotevi O,Ravel P.A decrease of regulatory T cells correlates with overall survival after sunitinib-based antiangiogenic therapy in metastatic renal cancer patients.J Immunother2010;33:991-8

[92] Ohm JE,Sempowski GD.VEGF inhibits T-cell development and may contribute to tumor-induced immune suppression.Blood2003;101:4878-86

[93] Rassy E,Albiges L.Tyrosine kinase inhibitors and immunotherapy combinations in renal cell carcinoma.Ther Adv Med Oncol2020;12:1758835920907504 PMCID:PMC7081462

[94] Wallin JJ,Funke R.Atezolizumab in combination with bevacizumab enhances antigen-specific T-cell migration in metastatic renal cell carcinoma.Nat Commun2016;7:12624 PMCID:PMC5013615

[95] Peng D,Nagarsheth N.Epigenetic silencing of TH1-type chemokines shapes tumour immunity and immunotherapy.Nature2015;527:249-53 PMCID:PMC4779053

[96] Mariathasan S,Nickles D.TGFβ attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells.Nature2018;554:544-8

[97] Granier C,Combe P.Tim-3 expression on tumor-infiltrating PD-1⁺CD8⁺ T cells correlates with poor clinical outcome in renal cell carcinoma.Cancer Res2017;77:1075-82

[98] Brignone C,Grygar C,Triebel F.A phase I pharmacokinetic and biological correlative study of IMP321, a novel MHC class II agonist, in patients with advanced renal cell carcinoma.Clin Cancer Res2009;15:6225-31

[99] Guo ZS,Bartlett DL.Oncolytic immunotherapy: dying the right way is a key to eliciting potent antitumor immunity.Front Oncol2014;4:74 PMCID:PMC3989763

[100] Gibney GT,DeConti RC.Safety, correlative markers, and clinical results of adjuvant nivolumab in combination with vaccine in resected high-risk metastatic melanoma.Clin Cancer Res2015;21:712-20 PMCID:PMC4620684

[101] Kim S,Lim S.Phase II trial of pexa-vec (pexastimogene devacirepvec; JX-594), an oncolytic and immunotherapeutic vaccinia virus, in patients with metastatic, refractory renal cell carcinoma (RCC).J Clin Oncol2018;36:671

[102] Gandhi S,Attwood K.Phase I clinical trial of combination propranolol and pembrolizumab in locally advanced and metastatic melanoma: safety, tolerability, and preliminary evidence of antitumor activity.Clin Cancer Res2021;27:87-95 PMCID:PMC7785669